Document Detail


Protecting the heart: a practical review of the statin studies.
MedLine Citation:
PMID:  12817199     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of this review of the landmark HMG-CoA reductase inhibitors (statins) studies is to enable the clinician to draw practical lessons from these trials. The Scandinavian Simvastatin Survival Study (4S) established the importance of treating the hypercholesterolemic patient with established cardiovascular heart disease. The West of Scotland Coronary Prevention Study (WOSCOPS) showed the benefit of treating healthy hypercholesterolemic men who were nevertheless at high risk of developing cardiovascular heart disease in the future. The Cholesterol and Recurrent Events (CARE) study, a secondary prevention trial, proved the benefit of treating patients with myocardial ischemia and cholesterol levels within normal limits. This conclusion was confirmed by the Long-term Intervention With Pravastatin in Ischemic Disease (LIPID) study, another secondary prevention study that enrolled patients with a wide range of cholesterol levels (4-7 mmol/dL), into which the large majority of patients would belong. The importance of treating patients with established ischemic heart disease (IHD), and those at high risk of developing cardiovascular heart disease, regardless of cholesterol level, was being realized. The Air Force/Texas Coronary Artery Prevention Study (AFCAPS/TexCAPS) then showed that treatment can reduce adverse cardiovascular events even in the primary prevention of patients with normal cholesterol levels. The Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) trial showed that hypocholesterolemic therapy is useful in the setting of an acute coronary syndrome, while the Atorvastatin Versus Revascularisation Treatment (AVERT) study showed that aggressive statin therapy is as good as angioplasty in reducing ischemic cardiac events in patients with stable angina pectoris. Finally, the Heart Protection Study (HPS) randomized more than 20,000 patients, and the value of statins in reducing adverse cardiovascular events in the high-risk patient, including the elderly, women, and even in those with low cholesterol levels, is beyond doubt. The emphasis is now on the risk level for developing cardiovascular events, and treatment should target the high-risk group and not be dependent on the actual cholesterol level of the patient. It is interesting to compare the large amount of data on the value and safety of the statins with the much more limited and less convincing data on antioxidant vitamins.
Authors:
H T Ong
Related Documents :
22422079 - Can augmentation index be used as an accurate tool in the diagnosis of peripheral obstr...
7211089 - Relation of platelet phospholipids to diabetic control.
22130279 - The role of peritoneal dialysis in the treatment of ascites.
14717719 - Relationship between hypercholesterolemia, lipid-lowering therapy and coronary flow vel...
21752669 - Persistent homocysteine metabolism abnormality accelerates cardiovascular disease in he...
22196759 - Proteomic analysis shows differential protein expression in endothelial progenitor cell...
11459909 - Motor neuron disease after electric injury.
11875669 - Humoral immunity and frequency of peritonitis in chronic peritoneal dialysis patients.
21396809 - Clinical and radiographic correlates of hypoxemia and oxygen therapy in the copdgene st...
Publication Detail:
Type:  Journal Article; Review     Date:  2002-12-10
Journal Detail:
Title:  MedGenMed : Medscape general medicine     Volume:  4     ISSN:  1531-0132     ISO Abbreviation:  MedGenMed     Publication Date:  2002 Dec 
Date Detail:
Created Date:  2003-06-20     Completed Date:  2003-07-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100894134     Medline TA:  MedGenMed     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1     Citation Subset:  IM    
Affiliation:
htyl@pd.jaring.my
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hypercholesterolemia / complications,  drug therapy,  etiology,  prevention & control*
Male
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gender differences in left ventricular chamber and midwall systolic function in normotensive and hyp...
Next Document:  Cancer clusters: findings vs feelings.